Berkeley Lights, Inc. (BLI) announced that Shire has purchased the Beacon platform to accelerate their cell line development (CLD) process. Shire's decision was based on a study that compared their existing CLD workflow to a workflow using the Beacon. Based on the pilot study, the Beacon platform was able to quickly and efficiently identify target secreting clones which saved resources while also accelerating the discovery and development process. The four modules of Berkeley Lights' Beacon platform – import, culture, assay, and export – can be applied for cell line development, antibody discovery and engineering, gene editing, and research. Automating workflows using the precise individual cell manipulation capabilities of the Beacon platform increases efficiencies and reduces overall time while providing insights into the behavior of clonal populations not possible using traditional techniques. Beacon is capable of screening thousands of clones in less than a week.